ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jeffrey L. Port
Robert J. Korst
Nasser K. Altorki
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Port, J. L.
Right arrow Articles by Altorki, N. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Port, J. L.
Right arrow Articles by Altorki, N. K.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2004;77:254-259
© 2004 The Society of Thoracic Surgeons

Original article: general thoracic

Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer

Jeffrey L. Port, MDa, Michael S. Kent, MDa, Robert J. Korst, MDa, Roger Keresztes, MDa, Matthew A. Levin, BSa, Nasser K. Altorki, MDa*

a Department of Cardiothoracic Surgery, Weill-Cornell Medical Center, New York, New York, USA

Accepted for publication July 17, 2003.

* Address reprint requests to Dr Altorki, Department of Cardiothoracic Surgery, Suite M404, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA.
e-mail: nkaltork{at}med.cornell.edu

BACKGROUND: The ability to accurately predict pathologic response to preoperative chemotherapy may have a significant impact on the treatment strategy for non-small cell lung cancer (NSCLC). The purpose of this study was to examine the accuracy of positron emission tomography (PET) scanning in predicting the pathologic response to preoperative chemotherapy in the primary tumor and draining lymph nodes.

METHODS: A total of 25 patients were enrolled in two separate phase II trials investigating induction chemotherapy for NSCLC. All patients underwent pre-treatment and post-treatment PET scans followed by surgical resection. A significant PET scan response was defined as a reduction in the standard uptake value by 50% or more. We defined a major pathologic response as either no disease or microscopic disease only in the primary tumor. The percentage change in standard uptake value was then calculated and correlated with pathologic response in the primary tumor. In addition, the presence or absence of nodal metastases as determined by the postchemotherapy PET scan was compared with final pathologic nodal stage.

RESULTS: The positive and negative predictive values for PET detection of major pathologic response in the primary tumor were 43% and 100%, respectively. Positron emission tomography did not accurately predict nodal status in 52% of patients. The positive and negative predictive values of PET to detect node-positive disease were 73% and 64%, respectively. For N2 disease the positive predictive value of PET scans was less than 20%.

CONCLUSIONS: Positron emission tomography scanning does not reliably predict pathologic response to preoperative chemotherapy in NSCLC in either the primary tumor or the draining lymph nodes.




This article has been cited by other articles:


Home page
 JCOHome page
F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul
Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer
J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. De Waele, M. Serra-Mitjans, J. Hendriks, P. Lauwers, J. Belda-Sanchis, P. Van Schil, and R. Rami-Porta
Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 824 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. E. Van Schil and M. De Waele
A second mediastinoscopy: how to decide and how to do it?
Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 703 - 706.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. Wang, Z. Wang, W. Yao, H. Xie, J. Xu, and L. Tian
Role of 99mTc-Octreotide Acetate Scintigraphy in Suspected Lung Cancer Compared with 18F-FDG Dual-Head Coincidence Imaging
J. Nucl. Med., September 1, 2007; 48(9): 1442 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer
Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend
Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT
J. Nucl. Med., May 1, 2007; 48(5): 744 - 751.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Serra, L. Occhionero, and D. Galetta
Complete Response Following Preoperative Chemotherapy for Resectable Non-small Cell Lung Cancer.
Chest, October 1, 2006; 130(4): 1284 - 1285.
[Full Text] [PDF]

Home page
 JCOHome page
P. De Leyn, S. Stroobants, W. De Wever, T. Lerut, W. Coosemans, G. Decker, P. Nafteux, D. Van Raemdonck, L. Mortelmans, K. Nackaerts, et al.
Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Leuven Lung Cancer Group Study
J. Clin. Oncol., July 20, 2006; 24(21): 3333 - 3339.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. J. Cerfolio, A. S. Bryant, and B. Ojha
Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med., March 1, 2006; 47(3): 451 - 469.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. De Waele, J. Hendriks, P. Lauwers, P. Ortmanns, W. Vanroelen, A.-M. Morel, P. Germonpre, and P. Van Schil
Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy
Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 240 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen
Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Am. J. Roentgenol., February 1, 2006; 186(2): 308 - 319.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al.
Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8362 - 8370.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group
Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database
Chest, September 1, 2005; 128(3): 1442 - 1447.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. Hellwig, T. P. Graeter, D. Ukena, T. Georg, C.-M. Kirsch, and H.-J. Schafers
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 892 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Cerfolio, A. S. Bryant, T. S. Winokur, B. Ohja, and A. A. Bartolucci
Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer
Ann. Thorac. Surg., December 1, 2004; 78(6): 1903 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. J. Wirth, A. T. Skarin, and D. J. Sugarbaker
Reply
Clin. Cancer Res., April 15, 2004; 10(8): 2904 - 2904.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The Society of Thoracic Surgeons.